CASZ1 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma cell line. This product features targeted disruption of the CASZ1 gene using CRISPR/Cas9 technology, generating a loss-of-function model for studying CASZ1-mediated transcriptional regulation in non-small cell lung cancer. The polyclonal population comprises a mix of editing events, providing a robust tool for functional genomics without the clonal biases inherent in single-cell-derived lines.
The NCI-H1975 parental line is a well-characterized model of non-small cell lung carcinoma, isolated from a patient with lung adenocarcinoma. It harbors the EGFR L858R activating mutation and the T790M gatekeeper mutation, which together render the cells resistant to most EGFR tyrosine kinase inhibitors. Consequently, NCI-H1975 is extensively employed to investigate mechanisms of acquired drug resistance and to test next-generation inhibitors that bypass or overcome EGFR blockade.
CASZ1 is a zinc finger transcription factor with established roles in cell fate determination, differentiation, and tumor suppression. It functions at the intersection of Notch and TGF??? signaling pathways, physically associating with chromatin remodeling complexes and histone deacetylases to orchestrate transcriptional programs. Among its direct targets are the cyclin-dependent kinase inhibitor CDKN1A (p21) and the oncogene MYCN, placing CASZ1 as a key regulator of cell cycle arrest and apoptosis. This integrative signaling network underscores how CASZ1 constrains malignant transformation by linking extracellular cues to gene expression.
In the NCI-H1975 lung cancer context, CASZ1 knockout is expected to relieve tumor suppressive constraints, potentially accelerating proliferation, enhancing survival, and increasing invasive capacity. The EGFR inhibitor-resistant background of the host line allows researchers to examine the interplay between CASZ1 loss and aberrant EGFR signaling in driving aggressive tumor behavior. This genetic perturbation model thus facilitates exploration of how transcriptional dysregulation contributes to drug resistance and aids in identifying synthetic lethal vulnerabilities.
These polyclonal CASZ1 knockout cells are well suited for a range of applications in lung cancer tumor biology, gene regulation, and drug resistance research. Typical experimental strategies include assessing cell viability and apoptosis under various drug treatments, performing migration and invasion assays, and monitoring gene expression changes via RT?qPCR, Western blotting, or RNA?seq. Combining phenotypic readouts with molecular profiling enables dissection of CASZ1-dependent pathways and evaluation of targeted therapeutic interventions. For additional information or technical assistance, please contact Ascent Research.
